Johnson & Johnson Gets Its Aprocitentan Money Back
Idorsia In a Fix Financially
Executive Summary
The US company has returned rights to the hypertension product to Idorsia, which was already in the grip of a cash crunch and will now face greater difficulties getting the drug to market.
You may also be interested in...
Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
Idorsia Makes Progress With Quviviq, But Needs Cash To Fund Big R&D And Launch Spending
Idorsia has a serious cashflow problem because of major R&D and drug launch commitments, but is banking on its blockbuster bets coming good, including two potential first-in-class cardiovascular drugs.
Idorsia/J&J’s Aprocitentan Hits Phase III Mark, Could Become First ET-1 Antagonist For Hypertension
The first-in-class ET-1 receptor antagonist has met the primary endpoint in a pivotal resistant hypertension trial, sparking filing plans that could see the drug establish a stronghold in the multi-billion dollar market.